SGLT2 inhibitor effects on artery stiffness, vessel lining thickness, and heart muscle after a heart attack
Official title: The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness , Left Atrial and Left Ventricular Deformation After Acute Myocardial Infarction
Run by University of Athens · NCT07469943 · Data updated 2026-11-12
This project will see if SGLT2 inhibitors given after a heart attack improve blood vessel stiffness, the vessel's protective lining, and heart muscle function for people with type 2 diabetes or reduced heart pumping.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University of Athens Academic / other |
| Locations | 1 site (Athens, Rimini1/Haidari) |
| Status | Recruiting |
| Started | January 9, 2026 |
| Main results expected | August 14, 2028 |
| Study ends | December 20, 2028 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT07469943 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with ST-elevation myocardial infarction who have type 2 diabetes or an LVEF <40% and who meet safety criteria (eGFR ≥60, not pregnant, no active cancer or autoimmune disease) are ideal candidates.
✕Probably not a fit
Patients with eGFR <60 ml/min/1.73 m², active malignancy, autoimmune/autoinflammatory disease, severe hepatic impairment, or who are pregnant or breastfeeding are excluded and unlikely to receive benefit as studied.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will follow people after ST-segment elevation myocardial infarction who have type 2 diabetes or a left ventricular ejection fraction below 40% to compare vascular and cardiac measures between those treated with SGLT2 inhibitors and those not treated. Investigators will record measurements of arterial stiffness, endothelial glycocalyx thickness, and myocardial deformation at baseline and during follow-up to track changes after the acute event. Key exclusions include significant chronic kidney disease (eGFR <60 ml/min/1.73 m²), active malignancy, autoimmune/autoinflammatory disorders, severe hepatic impairment, and pregnancy or breastfeeding. All study visits and measurements will be conducted at Attikon University Hospital in Athens as part of routine research follow-up.
Why it matters
Potential benefit: If positive, the findings could support using SGLT2 inhibitors to improve vascular function and limit adverse heart remodeling after myocardial infarction, potentially reducing heart failure and recurrent event risk.
How similar studies have gone: Large randomized trials have shown SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular death, but their specific effects on arterial stiffness, endothelial glycocalyx, and myocardial deformation after acute STEMI remain limited and underexplored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * STEMI participants with type 2 diabetes or LVEF\<40% Exclusion Criteria: 1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m² 2. Active malignancy 3. Autoimmune or autoinflammatory disorders 4. Severe hepatic impairment 5. Pregnancy or breastfeeding
Where it's running
-
Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens
Athens, Rimini1/Haidari, Greece Recruiting
Study contacts
- Study coordinator: Ignatios Ikonomidis, MD;PhD
- Email: ignoik@gmail.com
- Phone: 0030 6944805732
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Occupation-based lifestyle program for adults with type 2 diabetes
A online program tests whether an occupation-focused lifestyle plan helps adults with type 2 diabetes manage daily routines and feel better in life.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Optimal timing of staged complete revascularization in STEMI with multivessel disease
This trial tests whether performing staged complete revascularization during the hospital stay or after discharge is best for STEMI patients with multivessel disease.
-
Downhill walking training for type 2 diabetes
Researchers compare 8 weeks of downhill walking to level-ground walking in adults with type 2 diabetes to see which more improves walking ability and muscle and heart responses.
-
Normast 3 for adults with diabetic polyneuropathy
A 12-week trial will test whether Normast 3 helps reduce nerve pain in adults with diabetic polyneuropathy compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.